Youths in foster care have higher rates of psychotropic use, singly and concomitantly, than do youths who are eligible for Medicaid through income or disability qualifications. However, concomitant antipsychotic use among youth in foster care has not been assessed.
High rates of psychotropic use among youths in foster care is a major national concern, which has led to intense scrutiny about its appropriateness in this vulnerable population. Psychotropic prevalence for youth in foster care ranges from 14% to 30% in community settings [1] [2] [3] [4] and as high as 67% in therapeutic foster care and 77% in group homes. 5 Many youth in foster care receive more than 1 psychotropic medication, with as many as 22% using Ն2 medications from the same class. 6 Among youths with autism who were in foster care, 21% received Ն3 medications from different classes concomitantly for at least 30 days, compared with 10% among youths with autism and eligible for Medicaid through a disability status. 7 Finally, the increase has been primarily the second-generation antipsychotics (SGAs), [8] [9] [10] [11] [12] [13] [14] which carry a greater risk of metabolic adverse effects among children. 15 Concerning is the expanded use of antipsychotics for attention-deficit/hyperactivity disorder (ADHD) in the absence of schizophrenia, autism, or bipolar disorder for which these medications are typically prescribed. 16 In light of this evidence, the question raised here is whether antipsychotics are prescribed concomitantly for youth in foster care. Antipsychotic polypharmacy has increased among adults, [17] [18] [19] so it possible this is also occurring in youths. Given the lack of scientific evidence for such practice, the lack of data on the cumulative risks on child development, and the clear indications of the metabolic adverse effects with these agents, it is important to investigate concomitant antipsychotic use in this vulnerable child population. The purpose of this study was to examine concomitant antipsychotic treatment among youth in foster care compared with youth who met Medicaid eligibility for psychological, physical, and developmental impairment or financial need (ie, groups with distinctly different mental health needs). This information can aid state agencies in better understanding the challenges in delivering effective mental health care to youth placed in foster care, who typically have greater psychological impairment than youth in other Medicaid program categories. The university institutional review boards at the Johns Hopkins School of Medicine, the University of Pennsylvania, and the University of Maryland, Baltimore, approved this study and granted a waiver of informed consent.
PATIENTS AND METHODS

Design and Sample Selection
Medicaid fee-for-service and managed care claims data from 1 Mid-Atlantic state were used for a cross-sectional study of antipsychotic use in 2003. The 637 924 continuously Medicaidenrolled youths who were younger than 20 in 2003 constituted the population from which the study sample was selected. Continuous enrollment was defined as Ն335 of 365 days of Medicaid eligibility. The study sample was youth with (1) an inpatient or outpatient visit associated with a mental health diagnosis, and (2) a pharmacy claim for an antipsychotic medication in 2003. The criterion of at least 2 service or treatment encounters is an accurate method for identifying individuals engaged in mental health care using administrative data. [20] [21] [22] 
Data Sources
A unique identifier not traceable to personal identifiers or Medicaid number allowed data linkage across 3 separate Medicaid data files: enrollment; medical services; and pharmacy. Enrollment files identified eligibility dates, age, gender, race, and Medicaid program category (ie, foster care, disabled). Plan type was coded as fee-forservice versus managed care. International Classification of Diseases, Ninth Revision, psychiatric diagnostic codes obtained from health and behavioral health outpatient and inpatient claims were classified as ADHD, anxiety, autism, bipolar, conduct disorder, depression, oppositional defiant disorder, psychoses, schizophrenia, and substance abuse. Pharmacy claims for psychotropic medications were classified by major therapeutic class. The study targeted stimulants, antidepressants, antipsychotics, and moodstabilizers. Mood-stabilizing agents used in psychiatry included select anticonvulsants (carbamazepine, valproic acid, gabapentin, lamotrigine, and oxcarbazepine) and lithium.
Medicaid Program Categories
Medicaid program categories defined youth who were eligible because of an existing disability (ie, Supplemental Security Income [SSI]), involvement in foster care or adoption services, or Temporary Assistance for Needy Families (TANF). Youth in foster care may be adopted or removed/reunited with families, and thus they transition between foster care, adoption, or TANF. Moreover, those who remain longer in foster care are more likely to use mental health services 23 and might be characteristically different from youths who are adopted or are reunited with their family. Medicaid program category status, therefore, might denote characteristic differences that could potentially influence antipsychotic use. To assess this, multicategory involvement of youth in foster care was grouped as foster care only, foster care/SSI, foster care/TANF, or foster care/adoption.
Binary Measures of Antipsychotic Use
Antipsychotic use during the study year was defined as binary measures of any and concomitant use. First, youths who had at least 1 claim for an antipsychotic medication during the year were coded as any use. Youths with Ն2 different antipsychotic medications during the year were classified as nonoverlapping and overlapping days of use. Concomitant use was defined as overlap of Ն2 antipsychotics for Ͼ30 days. The goal was to capture concomitant use that did not reflect cross tapering.
Continuous Measure of Antipsychotic Use
A previously used method 24 was employed to establish the duration of concomitant antipsychotic use. First, days of use for each antipsychotic medication separately (ie, risperidone, quetiapine, etc) were estimated by using 2 key variables on each pharmacy claim: (1) medication-dispensing date and (2) the days of medication supplied. Days of use were organized into continuous treatment episodes for each antipsychotic medication. Continuous episodes were defined as consecutive medication claims with no more than 14 days between the end of 1 medication (ie, date dispensed ϩ days supply) and the start of a new medication (ie, date dispensed of the next prescription).
Next, concomitant antipsychotic treatment episode days were identified when Ն2 antipsychotics were used on the same day and this occurred for Ͼ30 days. Total duration of overlap was established as well as the unique days of any antipsychotic use (ie, not double-counting days of overlap).
Statistical Analyses
We used 2 
RESULTS
Characteristics of the Youth Sample
Of Overall, the sample was 70% male (n ϭ 11 842), 67% white (n ϭ 11 424), 21% black (n ϭ 3522), 19% aged 5 to 9 years, 44% aged 10 to 14 years, and 36% aged 15 to 19 years. Medicaid program category was distributed as follows: 52% (n ϭ 8787) SSI; 21% (n ϭ 3631) TANF; 14% (n ϭ 2310) foster care only; 5% (n ϭ 833) foster care/SSI; 4% (n ϭ 735) foster care/TANF; and 4% (n ϭ 673) foster care/adoption. Most (63%) were in managed care compared with 34% in fee-for-service.
Medicaid program category characteristics differed significantly ( Table  1 ). The largest proportion of males was in foster care only, foster care/ SSI, foster care/adoption, and SSI.
Older adolescents were predominantly in the foster care groups, children aged 5 to 14 years were mainly in foster care/adoption, SSI, and TANF; and preschool age children were mainly in TANF. Black youths comprised 21% overall who received antipsychotic medication and 37% of the foster careonly group. White youths comprised 67% of all antipsychotic users but 71% of the SSI antipsychotic-users. The majority of children across all program categories were in managed care, but there were significantly higher proportions of youth in TANF and SSI who received managed care relative to the foster care categories (P Ͻ .0001).
Psychiatric diagnoses also differed significantly across the Medicaid program categories (P Ͻ .0001; Table 1 ).
The most common diagnoses among the 16 969 youth who used antipsychotic medication were ADHD (53%) and depression (34%). Overall, 21% of youth had a bipolar disorder diagnosis; this ranged from 33% of youths in foster care/SSI to 15% of youths in TANF. On average, 5% of the antipsychotic-treated youth had a visit associated with a diagnosis of schizophrenia.
Antipsychotic use (16 714 of 16 969 [99%]) was almost exclusively a second-generation antipsychotic. The majority (56%) also received an antidepressant, which exceeded 60% in the foster care groups. Although 56% of the 16 969 youths received a stimulant medication, this was 71% in foster care/ adoption. Just about one-third was taking a mood-stabilizer, ranging from 52% in foster care/SSI to 24% in TANF.
Concomitant Antipsychotic Treatment
Duration of concomitant antipsychotic use differed significantly across Medicaid program categories ( 
DISCUSSION
This is the first study, to our knowledge, that examined concomitant antipsychotic use among subgroups of youth in foster care. After controlling for psychiatric diagnoses, other psychotropic use and demographic factors, youth who entered foster care were as likely to receive antipsychotics concomitantly for over 30 days as were disabled youth who typically have conditions for which antipsychotics are indicated. Antipsychotics have been used concomitantly for adults with schizophrenia, 26 but the rare prevalence among youths is not an explanation for the observed patterns. The data reveal that youths receive antipsychotics concomitantly primarily for conduct disorders. Of note, white youth were 27% less likely to receive concomitant antipsychotic treatment compared with black youths. Although the use patterns in the present study are concerning, better data on the clinical rationale, treatment outcomes, and safety are needed to assess the appropriateness and therapeutic benefit of such regimens.
There might be a number of clinical decisions for using antipsychotics concomitantly that are not captured in administrative data. For one, youths whose symptoms persist might require a higher dose. However, if unable to tolerate the adverse effects at the higher dose, a second agent with a different adverse effect profile might be prescribed to achieve a therapeutic effect and minimize the adverse effect burden. Second, concomitant use might have been for treatment of sleep problems, which would not have been detected in the claims data. Finally, a proportion might lack a reasonable clinical rationale. Unfortunately, it was not possible to determine which proportion of the prescribing is this latter group.
Nonetheless, concomitant antipsychotic use is not empirically supported. The evidence that does exist has been limited mainly to clozapine augmentation in treatment resistant patients. 27 Antipsychotic polypharmacy typically has demonstrated greater adverse effects with only marginal benefits. 27 The long-term use of concomitant antipsychotic medication carries important policy and practice implications given that approximately one-half of youth who enter the child welfare system have some emotional or behavioral problem, 28 but only 55% receive mental health services that align with national standards. 29 The mounting evidence of the increased risk associated with these agents has heightened public concern about antipsychotic prescribing in pediatrics, and specifically adverse metabolic effects 15, [30] [31] [32] [33] and the adequacy of monitoring and oversight. 34 Correll et al 31 compared antipsychotic dose in a pediatric sample of new SGA users on changes in weight and metabolic parameters. Dose was not significantly associated with weight gain, but olanzapine (Ͼ10 mg per day) and risperidone (Ͼ1.5 mg per day) were significantly related to increases in total cholesterol. 31 However, risperidone was the only SGA with a sufficient sample size to produce robust dose effect findings. There are no data on interactions, but given different receptor profiles it is a possibility, and the cP450 enzyme might have an important role. The incidence of weight gain, type 2 diabetes, and dyslipidemia among children and adolescents has been reported to be 2.3 to 5.3 times greater among those who receive multiple antipsychotics. 15 It is without question, given this evidence, that routine monitoring should be enforced. However, more than half of youths in foster care do not receive a medication evaluation. 35 Of youth in the New York State Medicaid program who were prescribed an antipsychotic in the 23 However, those who remain in foster care longer and use the most mental health services are the subset of most concern. Although no one method is perfect, Medicaid program category codes can be more easily reproduced by investigators who wish to replicate the study. Moreover, the continuously enrolled population is likely the most impaired subset of youth, and care patterns might be quite different for those who lose eligibility for various reasons. Small cell sizes resulting from the age by foster care group stratification limit robust subgroup analyses. Dosing was not assessed to determine if concomitant use was associated with lower daily doses. Others have reported that increases in antipsychotic use have not corresponded with increases in daily doses. 12 Antipsychotic duration is not a measure of compliance or consumption. Finally, the lack of information on illness severity, treatment decisions, and clinical outcomes prohibits conclusions about the appropriateness of treatment.
CONCLUSIONS
The growing complexity of antipsychotic medication use among youths calls for research on the effect of dosing and drug-drug interactions on weight gain and metabolic adverse effects. Longitudinal data are needed to determine if antipsychotic polypharmacy is preceded by failure of an adequate trial of monotherapy. Temporal associations among system-level policies, family factors, and youth factors and how this influences the use of complex psychotropic regimens will be important questions for future research. Fortunately, there is a national interest in establishing better oversight of psychotropic use among youth in foster care. Hopefully this will lead to better care coordination, less inappropriate prescribing, and better mental health care for youth in child welfare.
